Timely and authoritative, this volume brings together leading clinical researchers to describe contemporary applications of contingency management principles across a wide range of substance use disorders and patient populations. Contingency management uses a system of incentives and disincentives to motivate patients to meet their treatment goals, and has successfully been implemented in community treatment clinics, drug courts, and other settings. Featuring illustrative case material, the book presents a cogent empirical rationale and practical strategies for targeting major drugs of abuse and working with specific populations, including adolescents, pregnant women, and dually diagnosed and homeless individuals. Also addressed are the nuts and bolts of developing and funding contingency management programs. Critical Acclaim: "This book provides the most up-to-date summary of the broad range of applications of contingency management for substance abuse. Many practical examples bring to life the conceptual and empirical underpinnings of the approach. Well organized and comprehensive, this is a most useful text for training practitioners and students in an important therapeutic technique." —Thomas R. Kosten, MD, Jay H. Waggoner Chair and Professor of Psychiatry and Neuroscience, Baylor College of Medicine "This volume constitutes the state of the art of one of the most effective empirically based therapies for addiction. The contributors clearly lay out the fundamental approach, the breadth and depth of the application, and the utility of this treatment for addiction in its many forms. In my view, this book should be required reading for students, professionals working with addiction, and scientists."—Warren K. Bickel, PhD, Director, Center for Addiction Research, University of Arkansas for Medical Sciences Contents: 1. Introduction, Stephen T. Higgins and Kenneth Silverman I. Contingency Management Across Substances 2. Cocaine, Stephen T. Higgins, Sarah H. Heil, Randall E. Rogers, and Laura Chivers 3. Opioids, David H. Epstein and Kenzie L. Preston 4. Marijuana, Alan J. Budney and Catherine Stanger 5. Methamphetamines, John M. Roll and Thomas Newton 6. Tobacco, Stacey C. Sigmon, Richard J. Lamb, and Jesse Dallery 7. Alcohol, Conrad J. Wong, Kenneth Silverman, and George E. Bigelow 8. Medication Compliance, Bruce J. Rounsaville, Marc Rosen, and Kathleen M. Carroll II. Special Populations 9. Homeless Populations, Jesse B. Milby and Joseph Schumacher 10. Pregnant and Postpartum Women, Sarah H. Heil. Jin H. Yoon, and Stephen T. Higgins 11. People with Mental Illness, Jennifer W. Tidey and Rick Ries 12. Adolescents, Suchitra Krishnan-Sarin, Amy M. Duhig, and Dana Cavallo III. Dissemination 13. Large-Scale Dissemination Efforts in Drug Abuse Treatment Clinics, Maxine L. Stitzer and Scott Kellogg 14. Lowering Costs in Drug Abuse Treatment Clinics, Nancy M. Petry and Sheila M. Alessi 15. Use of Community Donations and Clinic Rebates to Fund Contingency Management in Community Treatment Clinics, Leslie Amass and Jonathan B. Kamien 16. Contingency Management in an Entitlement Rehabilitation Setting: An Example from the Veterans Health Administration, Charles Drebing, Bruce J. Rounsaville, and Robert Rosenheck 17. Employment-Based Reinforcement in the Treatment of Drug Addiction, Wendy D. Donlin, Todd W. Knealing, and Kenneth Silverman 18. Contingency Management in Adult Criminal Drug Courts, Douglas B. Marlowe and Conrad J. Wong Contributors: Sheila M. Alessi, PhD, Department of Psychiatry, University of Connecticut Health Center, Storrs, Connecticut Leslie Amass, PhD, Schering Plough Global Medical Affairs, Kenilworth, New Jersey George E. Bigelow, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland Alan J. Budney, PhD, Center for Addiction Research, Department of Psychiatry, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas Kathleen M. Carroll, PhD, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut Dana Cavallo, PhD, Substance Abuse Center, Yale University School of Medicine, New Haven, Connecticut Laura Chivers, MA, Department of Psychology, Harvard University, Cambridge, Massachusetts Jesse Dallery, PhD, Department of Psychology, University of Florida, Gainesville, Florida Wendy D. Donlin, PhD, Center for Learning and Health, Johns Hopkins University School of Medicine, Baltimore, Maryland Charles Drebing, PhD, New England Mental Illness Research Education and Clinical Center, Bedford VA Medical Center, Bedford, Massachusetts Amy M. Duhig, PhD, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut David H. Epstein, PhD, Clinical Pharmacology and Therapeutics Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland Sarah H. Heil, PhD, Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont Stephen T. Higgins, PhD, Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont Jonathan B. Kamien, PhD, BioPsych Consulting, Califon, New Jersey Scott Kellogg, PhD, Department of Psychology, New York University, New York, New York Todd W. Knealing, PhD, Department of Psychology, Briarcliff University, Sioux City, Iowa Suchitra Krishnan-Sarin, PhD, Department of Psychiatry, Yale University, New Haven, Connecticut Richard J. Lamb, PhD, Departments of Psychiatry and Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Douglas B. Marlowe, JD, PhD, Treatment Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania Jesse B. Milby PhD, Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama Thomas Newton, MD, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California Nancy M. Petry, PhD, Department of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut Kenzie L. Preston, PhD, Clinical Pharmacology and Therapeutics Research Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland Richard K. Ries, MD, Department of Psychiatry and Behavioral Sciences, University of Washington, and Harborview Medical Center, Seattle, Washington Randall E. Rogers, PhD, Substance Abuse Treatment Center, Burlington, Vermont John M. Roll, PhD, Washington Institute for Mental Illness Research and Training, Washington State University, Spokane, Washington Marc Rosen, MD, Department of Psychiatry, VA Connecticut Healthcare System, West Haven, Connecticut Robert Rosenheck, MD, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut Bruce J. Rounsaville, MD, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut Joseph Schumacher, PhD, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama Stacey C. Sigmon, PhD, Department of Psychiatry, University of Vermont, Burlington, Vermont Kenneth Silverman, PhD, Center for Learning and Health, Johns Hopkins University School of Medicine, Baltimore, Maryland Catherine Stanger, PhD, Center for Addiction Research, Department of Psychiatry, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas Maxine L. Stitzer, PhD, Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland Jennifer W. Tidey, PhD, Center for Alcohol and Addiction Studies, and Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island Conrad J. Wong, PhD, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky Jin H. Yoon, PhD, Department of Psychiatry, University of Vermont, Burlington, Vermont
|